Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 72

1.

Inducing iPSCs to escape the dish.

Barrilleaux B, Knoepfler PS.

Cell Stem Cell. 2011 Aug 5;9(2):103-11. doi: 10.1016/j.stem.2011.07.006. Review.

2.

Modulation of human allogeneic and syngeneic pluripotent stem cells and immunological implications for transplantation.

Sackett SD, Brown ME, Tremmel DM, Ellis T, Burlingham WJ, Odorico JS.

Transplant Rev (Orlando). 2016 Apr;30(2):61-70. doi: 10.1016/j.trre.2016.02.001. Epub 2016 Feb 10. Review.

3.

The genomic stability of induced pluripotent stem cells.

Chen Z, Zhao T, Xu Y.

Protein Cell. 2012 Apr;3(4):271-7. doi: 10.1007/s13238-012-2922-8. Epub 2012 Apr 19. Review.

4.

Human induced pluripotent stem cells--from mechanisms to clinical applications.

Drews K, Jozefczuk J, Prigione A, Adjaye J.

J Mol Med (Berl). 2012 Jul;90(7):735-45. doi: 10.1007/s00109-012-0913-0. Epub 2012 May 30. Review.

PMID:
22643868
5.

Molecular Obstacles to Clinical Translation of iPSCs.

Tapia N, Schöler HR.

Cell Stem Cell. 2016 Sep 1;19(3):298-309. doi: 10.1016/j.stem.2016.06.017. Epub 2016 Jul 21. Review.

PMID:
27452174
6.

Cells derived from iPSC can be immunogenic - yes or no?

Cao J, Li X, Lu X, Zhang C, Yu H, Zhao T.

Protein Cell. 2014 Jan;5(1):1-3. doi: 10.1007/s13238-013-0003-2.

7.

Induced pluripotent stem cell consensus genes: implication for the risk of tumorigenesis and cancers in induced pluripotent stem cell therapy.

Zhang G, Shang B, Yang P, Cao Z, Pan Y, Zhou Q.

Stem Cells Dev. 2012 Apr 10;21(6):955-64. doi: 10.1089/scd.2011.0649. Epub 2012 Feb 15.

PMID:
22185567
8.

Lack of immune response to differentiated cells derived from syngeneic induced pluripotent stem cells.

Guha P, Morgan JW, Mostoslavsky G, Rodrigues NP, Boyd AS.

Cell Stem Cell. 2013 Apr 4;12(4):407-12. doi: 10.1016/j.stem.2013.01.006. Epub 2013 Jan 24.

9.

Clinical therapy using iPSCs: hopes and challenges.

Lu X, Zhao T.

Genomics Proteomics Bioinformatics. 2013 Oct;11(5):294-8. doi: 10.1016/j.gpb.2013.09.002. Epub 2013 Sep 21. Review.

10.

Genetic and epigenetic variations in iPSCs: potential causes and implications for application.

Liang G, Zhang Y.

Cell Stem Cell. 2013 Aug 1;13(2):149-59. doi: 10.1016/j.stem.2013.07.001. Review.

11.

The potential for immunogenicity of autologous induced pluripotent stem cell-derived therapies.

Scheiner ZS, Talib S, Feigal EG.

J Biol Chem. 2014 Feb 21;289(8):4571-7. doi: 10.1074/jbc.R113.509588. Epub 2013 Dec 20. Review.

12.

The immunogenicity of cells derived from induced pluripotent stem cells.

Fu X.

Cell Mol Immunol. 2014 Jan;11(1):14-6. doi: 10.1038/cmi.2013.60. Epub 2013 Dec 16. Review.

13.

MicroRNAs contribute to induced pluripotent stem cell somatic donor memory.

Vitaloni M, Pulecio J, Bilic J, Kuebler B, Laricchia-Robbio L, Izpisua Belmonte JC.

J Biol Chem. 2014 Jan 24;289(4):2084-98. doi: 10.1074/jbc.M113.538702. Epub 2013 Dec 5.

14.

Induced pluripotent stem cells and their implication for regenerative medicine.

Csobonyeiova M, Polak S, Koller J, Danisovic L.

Cell Tissue Bank. 2015 Jun;16(2):171-80. doi: 10.1007/s10561-014-9462-9. Epub 2014 Jul 19. Review.

PMID:
25037593
15.

Malignant germ cell-like tumors, expressing Ki-1 antigen (CD30), are revealed during in vivo differentiation of partially reprogrammed human-induced pluripotent stem cells.

Griscelli F, Féraud O, Oudrhiri N, Gobbo E, Casal I, Chomel JC, Biéche I, Duvillard P, Opolon P, Turhan AG, Bennaceur-Griscelli A.

Am J Pathol. 2012 May;180(5):2084-96. doi: 10.1016/j.ajpath.2012.01.011. Epub 2012 Mar 13.

PMID:
22425713
16.

The tumourigenicity of iPS cells and their differentiated derivates.

Liu Z, Tang Y, Lü S, Zhou J, Du Z, Duan C, Li Z, Wang C.

J Cell Mol Med. 2013 Jun;17(6):782-91. doi: 10.1111/jcmm.12062. Epub 2013 May 26.

17.

Residual expression of reprogramming factors affects the transcriptional program and epigenetic signatures of induced pluripotent stem cells.

Sommer CA, Christodoulou C, Gianotti-Sommer A, Shen SS, Sailaja BS, Hezroni H, Spira A, Meshorer E, Kotton DN, Mostoslavsky G.

PLoS One. 2012;7(12):e51711. doi: 10.1371/journal.pone.0051711. Epub 2012 Dec 14.

18.

Reliable generation of induced pluripotent stem cells from human lymphoblastoid cell lines.

Barrett R, Ornelas L, Yeager N, Mandefro B, Sahabian A, Lenaeus L, Targan SR, Svendsen CN, Sareen D.

Stem Cells Transl Med. 2014 Dec;3(12):1429-34. doi: 10.5966/sctm.2014-0121. Epub 2014 Oct 8.

19.

Cartilage tissue engineering identifies abnormal human induced pluripotent stem cells.

Yamashita A, Liu S, Woltjen K, Thomas B, Meng G, Hotta A, Takahashi K, Ellis J, Yamanaka S, Rancourt DE.

Sci Rep. 2013;3:1978. doi: 10.1038/srep01978.

20.

Progress in the reprogramming of somatic cells.

Ma T, Xie M, Laurent T, Ding S.

Circ Res. 2013 Feb 1;112(3):562-74. doi: 10.1161/CIRCRESAHA.111.249235. Review.

Supplemental Content

Support Center